At 49, Jan Janisch-Hanzlik’s multiple sclerosis had transformed her life. Forced to give up her nursing job and live in fear of worsening symptoms, she enrolled in a groundbreaking CAR T cell therapy trial at the University of Nebraska Medical Center.
The treatment, originally designed for cancer, aims to reset the body's immune system by targeting cells that attack the self. For Janisch-Hanzlik, it represented both a ray of hope and an uncertain journey filled with potential side effects.
While many trials hold promise, questions remain about long-term efficacy and safety in autoimmunity cases. Janisch-Hanzlik’s decision to participate highlights the lengths patients are willing to go for a chance at relief from debilitating conditions.
The future of CAR T therapy looks promising but also complex. As more patients like Janisch-Hanzlik take part, researchers will continue to gather crucial data that could revolutionize how we treat autoimmune diseases in the years ahead.
